This ExpertREACT article was originally published on 14 December 2010. Events, market positions and pipeline statuses described reflect the state of knowledge at that date.
A different kind of year
For the vaccine industry, 2010 was a different year to 2009. While the industry continued making progress on revenue growth and new vaccine development, a series of setbacks reminded industry observers that the field remains as unpredictable as ever. The H1N1 "blip" that had been anticipated - the phasing out of pandemic vaccine revenue - was unfolding as expected. Pandemic vaccine producers GSK Biologicals, Sanofi Pasteur and Novartis Vaccines, who had benefited most in 2009-2010, were seeing decreases in 2011 reported sales in dollar terms, yet still managed to book approximately $3.5bn in H1N1 sales during 2010, with most recognised in Q1 as carry-over from government orders.
GSK Biologicals experienced a significant setback for its rotavirus vaccine Rotarix in 2010. In March, GSK disclosed that Rotarix contained material from porcine circovirus-1 (PCV-1). Although regulatory authorities noted PCV-1 did not replicate in humans and was unlikely to pose a safety risk, Rotarix was temporarily withdrawn from use in the US. After continued investigation, use was resumed in May 2010 but sales had declined by 40% by the time of the Q3 results. Merck & Co's RotaTeq was also found to contain PCV-1 and PCV-2 fragments, though at levels below the limits of detection posing no assessed safety risk.
Simplirix failure and manufacturing setbacks
In late September 2010, GSK halted development of its herpes vaccine Simplirix following results from the ongoing Herpevac trial conducted with the US National Institute of Allergy and Infectious Diseases (NIAID) since 2002. Although Simplirix had shown some efficacy in double HSV-seronegative women in an earlier Phase III trial, the Herpevac trial showed no efficacy against its primary endpoint for prevention of HSV-mediated disease. Additionally, Netherlands-based Crucell placed a temporary hold on shipments of its paediatric vaccine in October 2010 due to microbiological contamination - a further reminder of the manufacturing quality challenges inherent in vaccine production. H1N1 remained relevant epidemiologically, still accounting for approximately 20% of tested isolates in the US by December 2010.